Cabotegravir and hormone interaction study for HIV prevention
Treatments studied
Part of Infections clinical trials.
This study tests how a long-acting injectable HIV prevention drug (cabotegravir) works in people who also use hormone therapy (like birth control or gender-affirming hormones). The goal is to see if the hormones affect how well the drug prevents HIV. If you are HIV-negative, use hormones, and meet other health criteria, you may be able to join.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 19 or older.
- You must be HIV-negative and willing to stay on HIV prevention methods during the study.
- If you are a woman, you must use a non-hormonal birth control method and not be pregnant or breastfeeding.
- You must be willing to avoid taking any other HIV prevention medicines (including daily PrEP pills) during the study.
- You must be willing to use condoms for all anal or vaginal sex during the study.
- You must agree to avoid putting anything (including enemas, toys, or having sex) in the rectum or vagina for 3 days before and after each study procedure.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial provides cabotegravir, a long-acting injectable HIV medicine, for people who cannot take or absorb oral HIV medications. It is for those who have no other effective treatment options.
This Phase 3 study tests whether an injectable HIV prevention medicine (cabotegravir) given before exposure can help prevent HIV in people at higher risk. You may join if you are HIV-negative and meet specific sexual health, medication, and health-testing requirements.
This trial tests a long-acting injectable HIV prevention medication (cabotegravir) as an alternative to daily pills. It may be a good fit if you are a man who has sex with men and have been taking oral PrEP consistently.
This research studies how two types of long-acting birth control (a shot called cabotegravir and an implant) work in your body after pregnancy, and how they interact with HIV prevention or treatment. The study helps doctors understand the best doses and timing for women like you.
This Phase 1 study tests how the body handles a long-acting (slow-release) cabotegravir injection combined with a drug called hyaluronidase. It also checks safety and side effects in healthy adults to help future HIV-prevention or treatment plans.
This study tests a nurse-led program that offers a long-acting injectable medication (cabotegravir) to prevent HIV. The injection is given every two months, and the program aims to make it easier to access this prevention option at your local health center.
Hear when a new HIV trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.